MedTrace Logo

Live Attenuated Influenza Vaccine (LAIV) Versus Trivalent Inactivated Influenza Vaccine in Healthy Adults 18-49 Years

NCT03101462 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2019-03-06

Study results available
· View outcomes & findings →

Summary

This randomized, open-label, single-site study at Saint Louis University will enroll approximately 40 subjects who are healthy, 18 to 49 years old. Subjects will be randomized in a 1:1 fashion to receive either licensed trivalent FluMist containing (2010-2011 season appropriate), or licensed inactivated trivalent influenza vaccine (2010-2011 season appropriate) so that approximately 20 subjects will be randomized to receive LAIV, and 20 will receive IIV.

Conditions

Interventions

BIOLOGICAL

Inactivated Influenza Vaccine

BIOLOGICAL

Live Attenuated Influenza Vaccine

Sponsors & Collaborators

  • MedImmune LLC

    collaborator INDUSTRY

  • St. Louis University

    lead OTHER

Principal Investigators

  • Daniel F Hoft, MD, PhD · St. Louis University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-24
Primary Completion
2011-05-13
Completion
2011-11-09

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03101462 on ClinicalTrials.gov